Generate Biomedicines, Inc. 8-K

What Happened
Generate Biomedicines, Inc. announced that it filed an Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on March 2, 2026, effective immediately prior to the completion of its initial public offering (IPO). The company’s board and stockholders had previously approved the amended certificate and amended and restated bylaws, which also became effective with the Registration Statement.

Key Details

• The amended certificate authorizes 500,000,000 shares of common stock.
• The amended certificate eliminates references to the previously existing series of preferred stock and authorizes up to 10,000,000 shares of undesignated preferred stock, issuable in one or more series at the Board’s discretion.
• The amendments remove stockholders’ ability to act by written consent and to call special meetings of stockholders.
• The Amended and Restated Bylaws (previously approved) establish meeting procedures, an advance notice process for stockholder proposals and director nominations, and conform to the changes in the amended certificate.

Why It Matters
These charter and bylaw changes set the company’s corporate and governance framework for its public company status following the IPO. Key items for investors include the large authorized common share pool (500M), Board authority to create preferred stock series, and limits on certain stockholder actions (no written consents or special meeting calls), all of which affect corporate governance and potential future capital-raising flexibility.